Hikma Pharmaceuticals Plc Notice of GM (1042J)
April 25 2022 - 2:01AM
UK Regulatory
TIDMHIK
RNS Number : 1042J
Hikma Pharmaceuticals Plc
25 April 2022
FOR IMMEDIATE RELEASE
Hikma Pharmaceuticals PLC
25 April 2022
HIKMA PHARMACEUTICALS PLC
AGM UPDATE AND PUBLICATION OF EGM NOTICE
Withdrawal of 2022 AGM Resolution 15
The Board of Hikma Pharmaceuticals PLC ("Hikma" or the
"Company") today announces that it has decided to withdraw
Resolution 15 from the agenda of the Annual General Meeting ("2022
AGM") of the Company's shareholders to be held at 1.00 p.m. (London
time) today, 25 April 2022.
Resolution 15, as set out in the notice of the 2022 AGM (the
"2022 AGM Notice"), proposes the creation of distributable reserves
in the capital of the Company by means of a bonus issue and a
Court-sanctioned capital reduction (the "Relevant Business"). At
the 2022 AGM, Resolution 15 will be withdrawn from the business of
the meeting on account of a typographical error which resulted in
Resolution 15 being incorrectly proposed as an ordinary resolution,
rather than a special resolution, and consequently being of no
legal effect.
Save as set out above, the 2022 AGM will proceed as planned
later today in accordance with the arrangements previously
notified. The withdrawal of Resolution 15 does not otherwise affect
the validity of the 2022 AGM Notice, the proxy form or any proxy
votes already submitted on other proposed resolutions. The
numbering of all other proposed resolutions at the 2022 AGM will
remain unchanged.
Publication of EGM Notice
In order to allow the Relevant Business to be properly
considered by shareholders, the Company is today calling a separate
general meeting of its shareholders to be held at 10 a.m. on 20 May
2022 at Hikma Offices, 5th Floor, 1 New Burlington Place, London
W1S 2HR, United Kingdom (the "EGM"). The special resolution
relating to the Relevant Business will be the single item of
business at the EGM. Except to correct the typographical error in
connection with Resolution 15 of the 2022 AGM Notice, there will be
no changes to the text of the resolution or the accompanying
explanatory note, each as originally contained in the 2022 AGM
Notice.
Notice of the EGM will today be published and posted to those
shareholders on the Company's register of members as at the close
of business on 21 April 2022 who have elected to receive paper
communications. In compliance with the UK Financial Conduct
Authority's Listing Rules, the notice of EGM will shortly be
submitted to, and available for inspection from, the National
Storage Mechanism at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Full details of the business of, and arrangements for, the EGM
(including voting procedures) are contained in the notice of the
EGM. This announcement is not a substitute for reading the notice
of the EGM in full.
Peter Speirs
Company Secretary
For and on behalf of
Hikma Pharmaceuticals PLC
25 April 2022
Enquiries
Peter Speirs +44 (0)20 7399
Company Secretary 2772
About Hikma
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOGBKBBDPBKDOQB
(END) Dow Jones Newswires
April 25, 2022 02:01 ET (06:01 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024